Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30910364 | 0.85 | MEN1 (0.53) | MEN1KMT2AALDH1A1TP53LMNA | |
| SCHEMBL30038486 | 0.74 | MEN1 (0.52) | MEN1KMT2AALDH1A1TP53LMNA | |
| SCHEMBL29428717 | 0.73 | KMT2A (0.65) | MEN1KMT2AALDH1A1TP53LMNA | |
| SCHEMBL1325225 | 0.73 | KMT2A (0.65) | MEN1KMT2AALDH1A1TP53LMNA | |
| SCHEMBL27650617 | 0.72 | MEN1 (0.67) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL6171056 | 0.72 | MEN1 (0.67) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL29144204 | 0.72 | KMT2A (0.67) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL20203522 | 0.71 | MEN1 (0.47) | MEN1KMT2AALDH1A1TP53LMNA | |
| SCHEMBL16040909 | 0.71 | KDM4E (0.43) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1533879 | 0.70 | KMT2A (1.00) | MEN1KMT2AALDH1A1TP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240254113-A1 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2024-08-01 | — | — | US | disclosed |
| CN-117715897-A | Compounds and their use as CD38 inhibitors | 南京艾美斐生物医药科技有限公司 | 2024-03-15 | — | — | CN | disclosed |
| WO-2022228496-A1 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | NANJING IMMUNOPHAGE BIOTECH CO., LTD (CN) | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254113-A1 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | CD38, CD22, BCL6B | MEN1 2514/4885KMT2A 3009/4885ALDH1A1 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.